Skip to main content
PMC home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;9(2):275–284. doi: 10.1111/j.1750-3639.1999.tb00226.x

Paraneoplastic Neurologic Syndromes: Pathogenesis and Physiopathology

Josep Dalmau 1,3,✉, Humayun S Gultekin 2,3, Jerome B Posner 1,3
PMCID: PMC8098130  PMID: 10219745

Abstract

Since 1965 when the first paraneoplastic antineuronal antibody was reported by Wilkinson and Zeromski (55), the number of immunological responses detected in association with paraneoplastic syndromes of the nervous system has steadily increased. These responses are characterized by the presence of antineuronal antibodies in serum and CSF and/or infiltrates of T‐cells in the tumor and nervous system. A few syndromes are mediated by antibodies; they include those resulting from dysfunction of the neuromuscular junction at the pre‐ or post‐synaptic level (Lambert‐Eaton myasthenic syndrome, myasthenia gravis) or ion channel dysfunction in the peripheral nervous system (i.e, Voltage‐gated potassium channel and neuromyotonia). In most other paraneoplastic syndromes, including those involving the central nervous system, the pathogenic role of highly specific antineuronal antibodies (anti‐Hu, anti‐Yo, etc) has not been established; nevertheless these antibodies should be regarded as useful markers of specific paraneoplastic syndromes and tumors. Moreover, there is increasing evidence that in some of these syndromes T‐cell mediated mechanisms can cause the neurologic dysfunction and contribute to tumor rejection. Some paraneoplastic syndromes are caused by the tumor secretion of antibodies (macroglobulinemia and MAG antibodies), hormones, and cytokines. In other instances, the tumor may compete with the nervous system for an essential substrate (glucose, tryptophan) and result in neurologic dysfunction.

Full Text

The Full Text of this article is available as a PDF (146.5 KB).

References

  • 1. Ahern GL, O'Connor M, Dalmau J, Coleman A, Posner JB, Schomer DL, Herzog AG, Kolb DA, Mesulam M (1994) Paraneoplastic temporal lobe epilepsy with testicular neoplasm and atypical amnesia. Neurology 44: 1270–1274. [DOI] [PubMed] [Google Scholar]
  • 2. Alarcon‐Segovia D, Ruiz‐Arguelles A, Llorente L (1996) Broken dogma: penetration of autoantibodies into living cells. Immunol Today 17: 163–164. [DOI] [PubMed] [Google Scholar]
  • 3. Anderson NE, Rosenblum MK, Graus F, Wiley RG, Posner JB (1988) Autoantibodies in paraneoplastic syndromes associated with small‐cell lung cancer. Neurology 38: 1391–1398. [DOI] [PubMed] [Google Scholar]
  • 4. Benyahia B, Liblau R, Merle‐Béral H, Tourani J‐M, Dalmau J, Delattre J‐Y (1998) Cell‐mediated auto‐immunity in paraneoplastic neurologic syndromes with anti‐Hu antibodies. Ann Neurol, in press. [DOI] [PubMed] [Google Scholar]
  • 5. Bourin M, Hascoet M, Deguiral P (1996) 5‐HTP induced diarrhea as a carcinoid syndrome model in mice Fundam Clin Pharmacol 10: 450–457. [DOI] [PubMed] [Google Scholar]
  • 6. Brashear HR, Caccamo DV, Heck A, Keeney PM (1991) Localization of antibody in the central nervous system of a patient with paraneoplastic encephalomyeloneuritis. Neurology 41: 1583–1587. [DOI] [PubMed] [Google Scholar]
  • 7. Carpentier AF, Rosenfeld MR, Delattre J‐Y, Whalen RG, Posner JB, Dalmau J (1998) DNA vaccination with HuD inhibits tumor growth of a neuroblastoma in mice. Clin Cancer Res 4: 2819–2824. [PubMed] [Google Scholar]
  • 8. Dalmau J (1997) Paraneoplastic syndromes of the nervous system: General pathogeneic mechanisms and diagnostic approaches. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW, (Eds.), Volume 69, Chapter 17, pp. 319–328, Elsevier: Amsterdam . [Google Scholar]
  • 9. Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB (1990) Detection of the anti‐Hu antibody in the serum of patients with small cell lung cancer ‐ a quantitative western blot analysis. Ann Neurol 27: 544–552. [DOI] [PubMed] [Google Scholar]
  • 10. Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB (1991) Detection of the anti‐Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology 41: 1757–1764. [DOI] [PubMed] [Google Scholar]
  • 11. Dalmau J, Graus F, Cheung N‐KV, Rosenblum MK, Ho A, Caiñete A, Delattre JY, Thompson SJ, Posner JB (1995) Major histocompatibility proteins, anti‐Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 75: 99–109. [DOI] [PubMed] [Google Scholar]
  • 12. Dalmau J, Graus F, Rosenblum MK, Posner JB (1992) Anti‐Hu‐associated paraneoplastic encephalomyelitis/ sensory neuronopathy. A clinical study of 71 patients. Medicine 71: 59–72. [DOI] [PubMed] [Google Scholar]
  • 13. Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, Batchelor T, Gerstner E, Eichen J, Frennier J, Posner JB, Rosenfeld MR (1999) Mal, a novel neuronal and testis specific protein, is recognized by the serum of patients with paraneoplastic neurologic disorders. Brain 122: 27–39. [DOI] [PubMed] [Google Scholar]
  • 14. Dalmau JO, Posner JB (1997) Paraneoplastic syndromes affecting the nervous system. Semin Oncol 24: 318–328. [PubMed] [Google Scholar]
  • 15. Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB (1997) Motor neuron syndromes in cancer patients. Ann Neurol 41: 722–730. [DOI] [PubMed] [Google Scholar]
  • 16. Fukunaga H, Engel AG, Lang B, Newsom‐Davis J, Vincent A (1983) Passive transfer of Lambert‐Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 80: 7636–7640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Furneaux HM, Reich L, Posner JB (1990) Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 40: 1085–1091. [DOI] [PubMed] [Google Scholar]
  • 18. Gilbert JA, Bates LA, Ames MM (1995) Elevated aromatic‐L‐amino acid decarboxylase in human carcinoid tumors. Biochem Pharmacol 50: 845–850. [DOI] [PubMed] [Google Scholar]
  • 19. Giometto B, Marchiori GC, Nicolao P, Scaravilli T, Lion A, Bardin PG, Tavolato B (1997) Sub‐acute cerebellar degeneration with anti‐Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 23: 468–474. [DOI] [PubMed] [Google Scholar]
  • 20. Golan TD (1997) The nuclear compartment of living cells is not an absolute immunologically sequestered site: evidence for spontaneous intranuclear entry of lupus autoantibodies to living cells. Leukemia 11: 6–9. [DOI] [PubMed] [Google Scholar]
  • 21. Graus F, Dalmau J, Reñé R, Torà M, Malats N, Verschuuren JJ, Cardenal F, Viñolas N, García del Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX (1997) Anti‐Hu antibodies in patients with small cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 15: 2866–2872. [DOI] [PubMed] [Google Scholar]
  • 22. Graus F, Dalmau J, Valldeoriola F, Ferrer I, Reñé R, Marin C, Vecht ChJ, Arbizu T, Targa C, Moll JWB (1997) Immunological characterization of a neuronal antibody (anti‐Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 74: 55–61. [DOI] [PubMed] [Google Scholar]
  • 23. Graus F, Ribalta T, Campo E, Monforte R, Urbano A, Rozman C (1990) Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis. Neurology 40: 219–222. [DOI] [PubMed] [Google Scholar]
  • 24. Graus F, Segurado OG, Tolosa E (1988) Selective concentration of anti‐Purkinje cell antibody in the CSF of two patients with paraneoplastic cerebellar degeneration. Acta Neurol Scand 78: 210–213. [DOI] [PubMed] [Google Scholar]
  • 25. Greenlee JE, Parks TN, Jaeckle KA (1993) Type IIa (‘anti‐Hu’) antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology 43: 2049–2054. [DOI] [PubMed] [Google Scholar]
  • 26. Gultekin SH, Dalmau J, Graus Y, Posner JB, Rosenblum MK (1998) Anti‐Hu immunolabeling as an index of neuronal differentiation in human brain tumors: a study of 112 central neuroepithelial neoplasms. Am J Surg Pathol 22: 195–200. [DOI] [PubMed] [Google Scholar]
  • 27. Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, Morris C, Newsom‐Davis J (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41: 238–246. [DOI] [PubMed] [Google Scholar]
  • 28. Hormigo A, Dalmau J, Rosenblum M, River ME, Posner JB (1994) Immunological and pathological study of anti‐Ri associated encephalopathy. Ann Neurol 36: 896–902. [DOI] [PubMed] [Google Scholar]
  • 29. Hormigo A, Lieberman F (1994) Nuclear localization of anti‐Hu antibody is not associated with in vitro cytotoxicity. J Neuroimmunol 55: 205–212. [DOI] [PubMed] [Google Scholar]
  • 30. Jean WC, Dalmau J, Ho A, Posner JB (1994) Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti‐Hu‐associated paraneoplastic encephalomyelitis. Neurology 44: 140–147. [DOI] [PubMed] [Google Scholar]
  • 31. Lang B, Newsom‐Davis J, Wray D (1981) Autoimmune aetiology for myasthenic (Eaton‐Lambert) syndrome. Lancet 1: 224–226. [DOI] [PubMed] [Google Scholar]
  • 32. Lindstrom J, Shelton D, Fujii Y (1988) Myasthenia gravis. Adv Immunol 42: 233–284. [DOI] [PubMed] [Google Scholar]
  • 33. Mason WP, Graus F, Lang B, Honnorat J, Delattre J‐Y, Valldeoriola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom‐Davis J, Posner JB, Dalmau J (1997) Small‐cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert‐Eaton myasthenic syndrome. Brain 120: 1279–1300. [DOI] [PubMed] [Google Scholar]
  • 34. Miralles GD, O'Fallon JR, Talley NJ (1992) Plasma‐cell dyscrasia with polyneuropathy. N Engl J Med 327: 1919–1923. [DOI] [PubMed] [Google Scholar]
  • 35. Motomura M, Johnston I, Lang B, Vincent A, Newsom‐Davis J (1995) An improved diagnostic assay for Lambert‐Eaton myasthenic syndrome. J Neurol Neurosurg Psychiat 58: 85–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Nagel A, Engel AG, Lang B, Newsom‐Davis J, Fukuoka T (1988) Lambert‐Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann Neurol 24: 552–558. [DOI] [PubMed] [Google Scholar]
  • 37. Neumann H, Cavalie A, Jenne DE, Wekerle H (1995) Induction of MHC class I genes in neurons. Science 269: 549–552. [DOI] [PubMed] [Google Scholar]
  • 38. Newsom‐Davis J, Mills KR (1993) Immunological associations of acquired neuromyotonia (Isaac's syndrome). Report of five cases and literature review. Brain 116: 453–469. [DOI] [PubMed] [Google Scholar]
  • 39. Newsom‐Davis J, Murray NM (1984) Plasma exchange and immunosuppressive drug treatment in the Lambert‐Eaton myasthenic syndrome. Neurology 34: 480–485. [DOI] [PubMed] [Google Scholar]
  • 40. O'Neill JH, Murray NM, Newsom‐Davis J (1988) The Lambert‐Eaton myasthenic syndrome. A review of 50 cases. Brain 111: 577–596. [DOI] [PubMed] [Google Scholar]
  • 41. Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti‐Yo antibody positive patients. Neurology 42: 1931–1937. [DOI] [PubMed] [Google Scholar]
  • 42. Posner JB (1995) Neurologic Complications of Cancer. F.A.Davis Company: Philadelphia . [Google Scholar]
  • 43. Rowland LP, Sherman WH, Latov N, Lange DJ, McDonald TD, Younger DS, Murphy PL, Hays AP, Knowles D (1992) Amyotrophic lateral sclerosis and lymphoma: bone marrow examination and other diagnostic tests. Neurology 42: 1101–1102. [DOI] [PubMed] [Google Scholar]
  • 44. Schold SC, Cho ES, Somasundaram M, Posner JB (1979) Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol 5: 271–287. [DOI] [PubMed] [Google Scholar]
  • 45. Sillevis Smitt PA, Manley GT, Posner JB (1995) Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 45: 1873–1878. [DOI] [PubMed] [Google Scholar]
  • 46. Sillevis‐Smitt P, Manley G, Moll JWB, Dalmau J, Posner JB (1996) Pitfalls in the diagnosis of autoantibodies associated with paraneoplstic neurologic disease. Neurology 46: 1739–1741. [DOI] [PubMed] [Google Scholar]
  • 47. Sindic CJ, Andersson M, Boucquey D, Chalon MP, Bisteau M, Brucher JM, Laterre EC (1993) Anti‐Purkinje cells antibodies in two cases of paraneoplastic cerebellar degeneration. Acta Neurologica Belgica 93: 65–77. [PubMed] [Google Scholar]
  • 48. Strassmann G, Jacob CO, Fong M, Bertolini DR (1993) Mechanisms of paraneoplastic syndromes of colon‐26: involvement of interleukin 6 in hypercalcemia. Cytokine 5: 463–468. [DOI] [PubMed] [Google Scholar]
  • 49. Tanaka K, Tanaka M, Igarashi S, Onodera O, Miyatake T, Tsuji S (1995) Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti‐Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg 97: 101–105. [DOI] [PubMed] [Google Scholar]
  • 50. Tanaka M, Tanaka K, Onodera O, Tsuji S (1995) Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti‐Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg 97: 95–100. [DOI] [PubMed] [Google Scholar]
  • 51. Tora M, Graus F, De Bolos C, Real FX (1997) Cell surface expression of paraneoplastic encephalomyelitis/sensory neuronopathy‐associated Hu antigens in small‐cell lung cancers and neuroblastomas. Neurology 48: 735–741. [DOI] [PubMed] [Google Scholar]
  • 52. Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, Dalmau J (1996) Inflammatory infiltrates and complete absence of Purkinje cells in anti‐Yo‐associated paraneoplastic cerebellar degeneration. Acta Neuropathol (Berl) 91: 519–525. [DOI] [PubMed] [Google Scholar]
  • 53. Voltz R, Dalmau J, Posner JB, Rosenfeld MR (1998) T‐cell receptor analysis in anti‐Hu associated paraneoplastic encephalomyelitis. Neurology 51:1146–1150. [DOI] [PubMed] [Google Scholar]
  • 54. Voltz R, Gultekin H, Posner JB, Rosenfeld MR, Dalmau J (1998) Sera of patients with testicular cancer and paraneoplastic limbic/brainstem encephalitis harbor an antineuronal antibody (anti‐Ta) that recognizes a novel neuronal protein. J Neurol 245: 379. [Google Scholar]
  • 55. Wilkinson PC, Zeromski J (1965) Immunofluorescent detection of antibodies against neurons in sensory carcinomatous neuropathy. Brain 88: 529–538. [DOI] [PubMed] [Google Scholar]
  • 56. Younger DS, Rowland LP, Latov N, Hays AP, Lange DJ, Sherman W, Inghirami G, Pesce MA, Knowles DM, Powers J (1991) Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol 29: 78–86. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES